Unveiling 9 Analyst Insights On Legend Biotech
Portfolio Pulse from Benzinga Insights
Legend Biotech (NASDAQ:LEGN) received mixed analyst ratings with a shift towards bullish sentiment in the last quarter. The average 12-month price target was raised to $86.33 from $84.50, indicating a positive outlook. Analysts from firms like HC Wainwright & Co., UBS, Raymond James, RBC Capital, and Barclays adjusted their ratings and price targets, reflecting optimism about Legend Biotech's future performance. The company, engaged in novel cell therapies for oncology, showed a significant revenue growth rate of 187.57% as of December 31, 2023, but struggles with profitability and efficiency metrics.
April 01, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech's mixed analyst ratings have shifted towards a more bullish sentiment, with an increased average 12-month price target. The company's significant revenue growth contrasts with its profitability and efficiency challenges.
The increase in the average 12-month price target and the shift towards a more bullish sentiment among analysts suggest a positive short-term impact on LEGN's stock price. The significant revenue growth rate further supports this outlook, although concerns about profitability and efficiency metrics may temper gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100